Key statistics
Short selling activityProvided by S&P Global Market Intelligence
Open | 63.90 |
---|---|
High | 63.90 |
Low | 63.90 |
Bid | -- |
Offer | -- |
Previous close | 63.90 |
Average volume | -- |
---|---|
Shares outstanding | 61.20m |
Free float | 61.11m |
P/E (TTM) | 34.96 |
Market cap | 29.43bn EUR |
EPS (TTM) | 13.76 EUR |
Data delayed at least 15 minutes, as of Oct 12 2018.
More ▼
Announcements
- argenx Advances Clinical Development of ARGX-119 in Congenital Myasthenic Syndromes
- argenx Announces European Commission Approval of VYVGART Subcutaneous Injection for Chronic Inflammatory Demyelinating Polyneuropathy
- argenx Presents New Efgartigimod Data at EULAR 2025 Highlighting Positive Phase 2 Proof-of-Concept Results in Myositis and Sjogren’s Disease
- argenx to Present at Goldman Sachs 46th Annual Global Healthcare Conference
- argenx Announces Results of Annual General Meeting of Shareholders
- argenx Reports First Quarter 2025 Financial Results and Provides Business Update
- argenx to Present at BofA Securities 2025 Health Care Conference
- argenx to Report First Quarter 2025 Financial Results and Business Update on May 8, 2025
- argenx Announces Positive CHMP Opinion for VYVGART (efgartigimod alfa) Subcutaneous Injection for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
- argenx Announces Annual General Meeting of Shareholders on May 27, 2025
More ▼